{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"3390"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"PAN: C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.6","value":"2720"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"PAN: C1D8"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"BJB432: C1D1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"BJB432: C1D8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Vz/F: The apparent volume of distribution during terminal phase (associated with Lambda\\_z)","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PAS: Pharmacokinetic Analysis Set (PAS): The PK analysis set for PAN (PAS-PAN) consisted of all subjects with at least one evaluable PK concentration of PAN. The PK analysis set for BTZ (PAS-BTZ) consisted of all subjects with at least one evaluable PK concentration of BTZ.","reportingStatus":"POSTED","timeFrame":"Predose, 0.5h, 1h, 2h, 3h, 4h 8h, 24h 48h post dose","title":"Composite PharmacoKinetics (PK) of Panobinostat and Bortezomib: Vz/F","type":"SECONDARY","unitOfMeasure":"Litre (L)"}